A Reduction in ADAM17 Expression Is Involved in the Protective Effect of the PPAR-α Activator Fenofibrate on Pressure Overload-Induced Cardiac Hypertrophy
The peroxisome proliferator-activated receptor-α (PPAR-α) agonist fenofibrate ameliorates cardiac hypertrophy; however, its mechanism of action has not been completely determined. Our previous study indicated that a disintegrin and metalloproteinase-17 (ADAM17) is required for angiotensin II-induced...
Saved in:
Main Authors: | Si-Yu Zeng, Hui-Qin Lu, Qiu-Jiang Yan, Jian Zou |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-01-01
|
Series: | PPAR Research |
Online Access: | http://dx.doi.org/10.1155/2018/7916953 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cardiac secreted HSP90α exacerbates pressure overload myocardial hypertrophy and heart failure
by: Le Pan, et al.
Published: (2025-02-01) -
PPAR-α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia
by: Xiaomeng Feng, et al.
Published: (2015-01-01) -
ATP-Sensitive Potassium Channel Currents in Eccentrically Hypertrophied Cardiac Myocytes of Volume-Overloaded Rats
by: Zikiar V. Alvin, et al.
Published: (2011-01-01) -
Fenofibrate Inhibited the Differentiation of T Helper 17 Cells In Vitro
by: Zhou Zhou, et al.
Published: (2012-01-01) -
PPAR-Alpha Agonist Fenofibrate Combined with Octreotide Acetate in the Treatment of Acute Hyperlipidemia Pancreatitis
by: Wen Bao, et al.
Published: (2021-01-01)